Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.41, $0.13 better than the analyst estimate of $0.28. Revenue for the quarter came in at $182.5 million versus the consensus estimate of $171.98 million.

GUIDANCE:

Corcept Therapeutics sees FY2024 revenue of $675-700 million, versus the consensus of $661.1 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.